



Final Appraisal Recommendation

Advice number: 0122 – February 2022

Tirbanibulin (Klisyri®) 10 mg/g ointment

Submission by Almirall Ltd

Recommendation of the All Wales Medicines Strategy Group

Tirbanibulin (Klisyri®) is recommended as an option for use within NHS Wales for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.

Additional note(s):

- AWMSG noted there were no long-term safety data available for the medicine and is aware that long term safety will be assessed as part of a three-year post-authorisation study.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4076), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
0122:

Tirbanibulin (Klisyri®) 10 mg/g ointment. February 2022.